3-hydroxy-3-phenyl-2-propenedithioic acid | 41467-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-hydroxy-3-phenyl-2-propenedithioic acid
• 英文别名: 3-Hydroxy-3-phenyl-propen-(2)-dithiosaeure；3-Hydroxy-3-phenylprop-2-en-dithiosaeure；β-hydroxydithiocinnamic acid；beta-Hydroxydithiocinnamic acid；3-hydroxy-3-phenylprop-2-enedithioic acid
• CAS: 41467-11-2
• 化学式: C₉H₈OS₂
• 分子量: 196.294
• InChiKey: AZBFCAQPSUWKOK-UHFFFAOYSA-N

物化性质

• 沸点：
  319.8±52.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  [platinum(II)dichloride(1,2-bis(diphenylphosphino)ethane)] 、 3-hydroxy-3-phenyl-2-propenedithioic acid 在 NaOAc 作用下， 以 二氯甲烷 为溶剂， 以68%的产率得到(dppe)Pt{2-benzoyl-1,1-ethenedithiolate}
  参考文献：
  名称：

  Weigand, Wolfgang; Bosl, Gabriele; Polborn, Kurt, Chemische Berichte, 1990, vol. 123, # 6, p. 1339 - 1342

  摘要：

  DOI：
• 作为产物：
  描述：

  二硫化碳 、 苯乙酮 在 potassium tert-butylate 作用下， 以 异丙醚 为溶剂， 以80%的产率得到3-hydroxy-3-phenyl-2-propenedithioic acid
  参考文献：
  名称：

  二硫酸铜配合物在炔-叠氮环加成反应中的催化活性

  摘要：

  多种二硫酸铜配合物在不同温度下使用多种溶剂在铜催化的炔-叠氮化物环加成反应中表现出高催化活性，仅在 0.005 mmol 催化剂/mmol 炔烃或更少时表现出高效率。选择衍生自苯乙酮的二硫酸铜络合物作为催化剂制备 1,4-二取代-1,2,3-三唑库。该过程以高产率和良好的官能团耐受性发生。

  DOI：

  10.1139/cjc-2012-0325

文献信息

• (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds
  作者：Gustavo Pretelín-Castillo、Mayra Silva Miranda、Clara Espitia、Rosa María Chávez-Santos、Abel Suárez-Castro、Luis Chacón-García、Rodrigo Aguayo-Ortiz、Roberto Martinez

  DOI：10.2147/idr.s328132

  日期：——

  phenyl ring of a 3-hydroxy-3-phenyl-prop-2-enedithioic acid scaffold (compounds 11a–j) in inhibiting the growth of M. tuberculosis strain H37Rv. Methods: (Z)-3-hydroxy-3-(4-R-phenyl)-prop-2-enedithioic acids 11b–j, with R groups including various electron-donating or electron-withdrawing groups, were designed by structurally modifying the lead compound 11a. The syntheses of 11a–j involved each one-step

  背景：结核病是一种由结核分枝杆菌引起的传染病。包括含硫支架在内的化合物已被证明是各种抗结核药物中的关键支架。有趣的是，据我们所知，3-羟基-3-苯基-丙-2-烯二硫代酸11a-j以前没有被描述为抗结核药物。 目的：在本研究中，我们研究了连接到 3-羟基-3-苯基-丙-2-烯二硫酸支架（化合物11a-j ）苯环上的取代基在抑制结核分枝杆菌菌株生长中的作用H37Rv。 方法：(Z)-3-hydroxy-3-(4-R-phenyl)-prop-2-enedithioic acid 11b-j，R 基团包括各种给电子或吸电子基团，是通过对先导化合物进行结构修饰而设计的11a。11a-j的合成涉及从相应的取代苯乙酮开始的每个一步程序。化合物11a-j针对M. tuberculosis菌株 H37Rv 进行了测试，以评估它们的细菌生长抑制活性。通过采用三种不同的方法预测 ADMET 配置文件。此外，基
• Synthesis, Characterization, and Tautomerism of Four Novel Copper(I) Complexes from 3-Hydroxy-3-(<i>p</i>-R-phenyl)-2-propenedithioic Acids
  作者：Ivan García-Orozco、José G. López-Cortés、M. Carmen Ortega-Alfaro、Rubén Alfredo Toscano、Guillermo Penieres-Carrillo、Cecilio Alvarez-Toledano

  DOI：10.1021/ic0488132

  日期：2004.12.1

  The paper describes the synthesis and structural characterization of four novel copper(I) complexes [CuL(PPh(3))(2)] (L = 3-hydroxy-3-(p-R-phenyl)-2-propenedithioate). In addition, a tautomeric equilibrium in solution was found and Hammett correlations with (13)C NMR parameters were studied. The structure of one complex was fully established by X-ray diffraction analysis.

  该论文描述了四种新型铜（I）配合物[CuL（PPh（3））（2）]（L = 3-羟基-3-（pR-苯基）-2-丙二硫代乙酸酯）的合成和结构表征。此外，发现溶液中存在互变异构平衡，并研究了与（13）C NMR参数的Hammett相关性。通过X射线衍射分析完全确定了一种络合物的结构。
• [EN] DNA-PK INHIBITORS<br/>[FR] INHIBITEURS D'ADN-PK
  申请人：CANCER REC TECH LTD

  公开号：WO2003024949A1

  公开（公告）日：2003-03-27

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R?1 and R2¿ are independently hydrogen, an optionally substituted C¿1-7? alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR?4¿ and O, O and CR'4 and NR'4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R?3 and R4 or R'4¿ is an optionally substituted C¿3-20? heteroaryl or C5-20 aryl group, and the other of R?3 and R4 or R'4¿ is H, or R?3 and R4 or R'4¿ together are -A-B-, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式和前药，在制备用于抑制DNA-PK活性的药物中使用，其中R?1和R2¿分别为氢、可选取代的C¿1-7?烷基、C3-20杂环基或C5-20芳基，或者可以与它们连接的氮原子一起形成具有4到8个环原子的可选取代杂环环；X和Y从CR?4¿和O、O和CR'4和NR'4和N中选取，其中不饱和度在环中适当位置，其中R?3和R4或R'4¿中的一个为可选取代的C¿3-20?杂芳基或C5-20芳基，而另一个为H，或者R?3和R4或R'4¿一起是-A-B-，它们共同代表一个融合的可选取代芳香环。这些化合物还比PI 3-激酶和/或ATM选择性地抑制DNA-PK活性。
• Dna-pk inhibitors
  申请人：——

  公开号：US20040192687A1

  公开（公告）日：2004-09-30

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are —A—B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM. 1

  本发明涉及使用式(I)化合物及其异构体、盐、溶剂合物、化学保护形式及其前药，在制备抑制DNA-PK活性的药物方面使用。其中，R1和R2分别为氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成含有4到8个环原子的可选取代杂环环；X和Y从CR4和O、O和CR'4以及NR"4和N中选择，其中不饱和度在环中适当位置，且R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为氢，或者R3和R4或R"4一起为-A-B-，它们共同表示一个融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，也具有选择性抑制DNA-PK活性的作用。
• DNA-PK INHIBITORS
  申请人：Martin Morrison Barr Niall

  公开号：US20070238729A1

  公开（公告）日：2007-10-11

  The invention relates to the use of compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, in the preparation of a medicament for inhibiting the activity of DNA-PK, wherein R 1 and R 2 are independently hydrogen, an optionally substituted C 1-7 alkyl group, C 3-20 heterocyclyl group, or C 5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; X and Y are selected from CR 4 and O, O and CR′ 4 and NR″ 4 and N, where the unsaturation is in the appropriate place in the ring, and where one of R 3 and R 4 or R′ 4 is an optionally substituted C 3-20 heteroaryl or C 5-20 aryl group, and the other of R 3 and R 4 or R′ 4 is H, or R 3 and R 4 or R″ 4 together are -A-B—, which collectively represent a fused optionally substituted aromatic ring. The compounds also selectively inhibit the activity of DNA-PK compared to PI 3-kinase and/or ATM.

  本发明涉及使用式(I)的化合物及其异构体、盐、溶剂合物、化学保护形式和前药，在制备抑制DNA-PK活性的药物方面有用。其中，R1和R2独立地表示氢、可选取代的C1-7烷基、C3-20杂环基或C5-20芳基，或者与它们连接的氮原子一起形成可选取代的含有4到8个环原子的杂环环；X和Y选自CR4和O，O和CR'4以及NR"4和N，其中不饱和度在环中适当位置，其中R3和R4或R'4中的一个为可选取代的C3-20杂芳基或C5-20芳基，而另一个为H，或者R3和R4或R"4在一起为-A-B-，代表一种融合的可选取代芳香环。这些化合物与PI 3-激酶和/或ATM相比，具有选择性地抑制DNA-PK的活性。